Recent studies have suggested cerebellar atrophy caused by Dilantin (phenytoin) is a distinct possibility for patients who are long-term users of the medication or are on a heavy dose prescription. Patients and prescribing physicians have become increasingly concerned over cases that appear to be cerebellar atrophy caused by Dilantin, following several studies indicating a correlation.

According to the FDA, there have been multiple alleged cases of cerebellar atrophy among Dilantin patients. The agency states this condition was observed in several Dilantin patients, who reportedly experienced serious damage to their cerebellum. This damage caused them to suffer problems with basic movements like walking, along with problems in swallowing and speaking.

Case Studies Suggest Cerebellar Atrophy Caused by Dilantin

The agency’s warning also stems from the findings of several recent studies that point to cerebellar atrophy caused by Dilantin.

One of these studies was published in 2013 in Neurology Asia, which investigated a case report of a Dilantin patient who suffered severe cerebellar damage. The patient displayed both physical and cognitive defects soon after starting the Dilantin prescription, leading the researchers to state that “persistent cerebellar dysfunction with cerebellar atrophy is a well-known complication of long-term phenytoin use”.

Another report published in 2008 in the Journal of Clinical Pharmacy and Therapeutics, researchers highlighted the link between Dilantin exposure to cerebellar damage. The scientists also observed cases where doctors missed the cerebellar atrophy diagnosis. In each of these cases, the patient reportedly exhibited symptoms similar to cerebellar lesion or intoxication.

Overview of Dilantin Cerebellar Atrophy Correlation

Cerebellar atrophy is the degeneration of the cerebellum, which sits under the cerebrum and behind the brainstem. Divided into two hemispheres, the cerebellum is responsible for speech and muscle movement that allow the patient balance, muscle control, coordination, and speech.

When the cerebellum becomes damaged, the patient may experience problems with speech and movement.

Symptoms of cerebellar atrophy have also been compared to those of stroke. These symptoms may include:

• Unsteady Walking Gait
• Jerky or Unsteady Movements in Arms or Legs
• Slow and Slurred Speech
• Nystagmus (Small Rapid Eye Movements)

While treatment of cerebellar atrophy varies between patients, some patients have reportedly recovered from early stages of the disease when going through monitored withdrawal. However, more severe cases have caused patients to suffer permanent complications, which can be managed through medications or physical therapy.

Dilantin is a popular anticonvulsant medication that has been on the market for decades, often used to treat a variety of epileptic conditions. Cerebellar damage is one of the most devastating side effects, as it can permanently affect the patient’s muscle control.

Patients who have allegedly developed cerebellar atrophy caused by Dilantin may be able to file legal action against the drug’s manufacturer Pfizer Inc. for failing to adequately warn them against this potential side effect. A consultation with a knowledgeable pharmaceutical lawyer can help potential claimants determine their eligibility for a Dilantin cerebellar atrophy lawsuit.